GRCL
Price:
$10.25
Market Cap:
$7.01B
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-...[Read more]
Industry
Biotechnology
IPO Date
2021-01-08
Stock Exchange
NASDAQ
Ticker
GRCL
According to Gracell Biotechnologies Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 7.73. This represents a change of 13.67% compared to the average of 6.80 of the last 4 quarters.
The mean historical Current Ratio of Gracell Biotechnologies Inc. over the last ten years is 12.72. The current 7.73 Current Ratio has changed 5.98% with respect to the historical average. Over the past ten years (40 quarters), GRCL's Current Ratio was at its highest in in the December 2019 quarter at 18.74. The Current Ratio was at its lowest in in the March 2020 quarter at 0.
Average
12.72
Median
12.15
Minimum
6.78
Maximum
18.74
Discovering the peaks and valleys of Gracell Biotechnologies Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 39.13%
Maximum Annual Current Ratio = 18.74
Minimum Annual Increase = -53.38%
Minimum Annual Current Ratio = 6.78
Year | Current Ratio | Change |
---|---|---|
2022 | 6.78 | -44.21% |
2021 | 12.15 | 39.13% |
2020 | 8.73 | -53.38% |
2019 | 18.74 | 8.93% |
The current Current Ratio of Gracell Biotechnologies Inc. (GRCL) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
9.22
5-year avg
12.72
10-year avg
12.72
Gracell Biotechnologies Inc.’s Current Ratio is less than Theseus Pharmaceuticals, Inc. (29.93), greater than Monte Rosa Therapeutics, Inc. (6.56), less than Design Therapeutics, Inc. (41.42), less than Erasca, Inc. (16.79), less than NextCure, Inc. (8.35), greater than CytomX Therapeutics, Inc. (1.00), less than Neoleukin Therapeutics, Inc. (15.33), greater than Spero Therapeutics, Inc. (2.68), greater than Assembly Biosciences, Inc. (2.74), less than Terns Pharmaceuticals, Inc. (21.02), greater than Amylyx Pharmaceuticals, Inc. (4.66), less than Acumen Pharmaceuticals, Inc. (17.37), less than Inozyme Pharma, Inc. (9.84), greater than X4 Pharmaceuticals, Inc. (6.07), greater than Bolt Biotherapeutics, Inc. (4.28), greater than Coherus BioSciences, Inc. (1.21), less than Icosavax, Inc. (18.06), greater than Day One Biopharmaceuticals, Inc. (4.09), greater than Decibel Therapeutics, Inc. (3.03), greater than Blueprint Medicines Corporation (3.71),
Company | Current Ratio | Market cap |
---|---|---|
29.93 | $181.50M | |
6.56 | $349.21M | |
41.42 | $264.42M | |
16.79 | $807.96M | |
8.35 | $39.73M | |
1.00 | $93.74M | |
15.33 | $8.20M | |
2.68 | $71.07M | |
2.74 | $107.81M | |
21.02 | $549.60M | |
4.66 | $161.36M | |
17.37 | $133.38M | |
9.84 | $312.42M | |
6.07 | $109.78M | |
4.28 | $24.78M | |
1.21 | $142.86M | |
18.06 | $769.04M | |
4.09 | $1.25B | |
3.03 | $123.37M | |
3.71 | $5.47B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gracell Biotechnologies Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Gracell Biotechnologies Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Gracell Biotechnologies Inc.'s Current Ratio?
How is the Current Ratio calculated for Gracell Biotechnologies Inc. (GRCL)?
What is the highest Current Ratio for Gracell Biotechnologies Inc. (GRCL)?
What is the 3-year average Current Ratio for Gracell Biotechnologies Inc. (GRCL)?
What is the 5-year average Current Ratio for Gracell Biotechnologies Inc. (GRCL)?
How does the current Current Ratio for Gracell Biotechnologies Inc. (GRCL) compare to its historical average?